Capastat Side Effects
Generic name: capreomycin
Note: This document contains side effect information about capreomycin. Some of the dosage forms listed on this page may not apply to the brand name Capastat.
Some side effects of Capastat may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to capreomycin: injection powder for solution
Along with its needed effects, capreomycin (the active ingredient contained in Capastat) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor as soon as possible if any of the following side effects occur while taking capreomycin:More common
- Greatly increased or decreased frequency of urination or amount of urine
- increased thirst
- loss of appetite
- Any loss of hearing
- clumsiness or unsteadiness
- difficulty in breathing
- irregular heartbeat
- muscle cramps or pain
- pain, redness, hardness, unusual bleeding, or a sore at the place of injection
- ringing or buzzing or a feeling of fullness in the ears
- skin rash
- unusual tiredness or weakness
For Healthcare Professionals
Applies to capreomycin: intramuscular powder for injection
Renal side effects have included dose-related nephrotoxicity, including BUN elevations (greater than 20 mg/dL) (36%), BUN elevations (greater than 30 mg/dL) (10%), depression of PSP excretion, abnormal urine sediment, renal insufficiency, and oliguria. At least one case of toxic nephritis and acute tubular necrosis has been reported.
A patient with tuberculosis and portal cirrhosis experienced toxic nephritis and acute tubular necrosis coincident with capreomycin therapy. The patient was treated with capreomycin therapy (1 g) and aminosalicylic acid daily for 1 month. The patient developed renal insufficiency and oliguria and died. The autopsy showed subsiding acute tubular necrosis.
Nervous system side effects have included ototoxicity and vestibular toxicity including subclinical auditory loss (11%), clinically apparent hearing loss (3%), vertigo, and tinnitus.
Local side effects have included pain, induration, and excessive bleeding at the injection site.
Hematologic side effects have included leukocytosis, leukopenia, and eosinophilia. Thrombocytopenia has also been reported rarely.
Hepatic side effects have included decreased BSP excretion.
Metabolic side effects including hypokalemia, hypocalcemia, hypomagnesemia, and electrolyte disturbances resembling Bartter's syndrome have been reported.
More Capastat resources
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.